Vertex Pharmaceuticals is laying off 125 employees and consolidating their Rhode Island buildings after a failed diabetes ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 2.68% on an annualized basis producing an ...

Vertex Pharmaceuticals Inc. closed 13.15% short of its 52-week high of $519.88, which the company reached on November 8th.

Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 2:40 PM ET David M. Altshuler - Executive VP & Chief Scientific Officer ...

Vertex has built its earnings thanks to its CF program, and with a new CF drug approved a few months ago, the company may be ...

As a company, Vertex says, “We strike at the core of serious diseases to change people’s lives. Bringing together the ...

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Eli Lilly has reached a deal to acquire SiteOne Therapeutics that would give it control of a non-opioid pain drug that would ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) presented promising clinical data on their CFTR modulator ALYFTREK at the European Cystic Fibrosis Conference, showcasing improved outcomes for patients with ...

Vertex Pharmaceuticals Inc. closed 14.97% short of its 52-week high of $519.88, which the company achieved on November 8th.

US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) has announced data across multiple studies demonstrating positive clinical ...

Vertex Pharmaceuticals (NASDAQ:VRTX) will release its quarterly earnings report on Monday, 2025-05-05. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Vertex ...